申请人:Senju Pharmaceutical Co., Ltd.
公开号:EP0806422A2
公开(公告)日:1997-11-12
Compounds represented by the general Formula (I);
wherein A represents a pyrimidine ring, R1 and R2 represent independently hydrogen or optionally substituted C1-6 alkyl or alkoxy and salts thereof are effective for preventing or treating cataract by oral or parenteral administration. The pyrimidine ring can be attached to the piperazine ring at a carbon or nitrogen atom of the piperazine ring.
通式(I)所代表的化合物;其中A代表嘧啶环,R1和R2分别代表氢或可选取代的C1-6烷基或烷氧基,以及其盐,可以通过口服或静脉注射有效地预防或治疗白内障。嘧啶环可以连接到哌嗪环的一个碳或氮原子上。